|
Myeloid Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
His-1 and His-2: identification and chromosomal mapping of two commonly rearranged sites of viral integration in a myeloid leukemia.
|
1682866 |
1991 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy.
|
17671421 |
2007 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy.
|
17671421 |
2007 |
|
Progression of prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Hexim-1 modulates androgen receptor and the TGF-β signaling during the progression of prostate cancer.
|
22095517 |
2012 |
|
Left Ventricular Hypertrophy
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Hexamethylene bis-acetamide inducible protein 1 (HEXIM1) is a negative regulator of positive transcription elongation factor b (P-TEFb), which activates RNA polymerase II (RNAPII)-dependent transcription and whose activation is strongly associated with left ventricular hypertrophy.
|
23300697 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression.
|
27058786 |
2016 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression.
|
27058786 |
2016 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.
|
27903752 |
2017 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
HEXIM1 is described as an excellent pharmacodynamic biomarker for target engagement in tumors as well as in blood.
|
29491412 |
2018 |
|
Drug Dependence
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A variant of the ADH1B gene (rs1229984 or rs1229984;rs750891770;s750891770" genes_norm="125;64129">Arg48His; previously referred to as Arg [*1] and His [*1]) has been reported to be associated with reduced rates of alcohol and drug dependence.
|
21497796 |
2011 |
|
Amelogenesis Imperfecta
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An identified human enamelin BAC genomic clone was shown to contain markers D4S2604 and D4S2670, as well as the first exon of the human ameloblastin gene, placing enamelin in the critical amelogenesis imperfecta locus between markers HIS1 and D4S2604 at 4q21.
|
11037750 |
2000 |
|
Hypertensive disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Cardiomyocyte-specific overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced pulmonary hypertension in mice.
|
23300697 |
2012 |
|
Mammary Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Clinically relevant HEXIM1 activities that are also induced by 4a1 include enhancement of the inhibitory effects of tamoxifen and inhibition of breast tumor metastasis.
|
27238569 |
2016 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Clinically relevant HEXIM1 activities that are also induced by 4a1 include enhancement of the inhibitory effects of tamoxifen and inhibition of breast tumor metastasis.
|
27238569 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Correspondingly, cytoplasmic localization of endogenous HEXIM1 is detected in an acute myeloid leukemia (AML) cell line containing the NPMc+ mutation, suggesting the physiological importance of HEXIM1-NPMc+ interaction.
|
18371977 |
2008 |
|
Left Ventricular Hypertrophy
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Decreased Hexim-1 expression in animal models of chronic diseases such as left ventricular hypertrophy, obesity and cancer triggered significant changes in adaptation and remodeling.
|
28013147 |
2017 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Decreased Hexim-1 expression in animal models of chronic diseases such as left ventricular hypertrophy, obesity and cancer triggered significant changes in adaptation and remodeling.
|
28013147 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Decreased Hexim-1 expression in animal models of chronic diseases such as left ventricular hypertrophy, obesity and cancer triggered significant changes in adaptation and remodeling.
|
28013147 |
2017 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, overexpression of SphK1 increased S1P levels, and the exogenous addition of S1P increased liver cell migration and invasion through the EDG1 receptor.
|
22098666 |
2012 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In melanoma, we identify HEXIM1, a transcription elongation regulator, as a melanoma tumor suppressor that responds to nucleotide stress.HEXIM1 expression is low in melanoma.
|
27058786 |
2016 |
|
Adenocarcinoma of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this report, we observed that Hexim-1 protein expression is absent in normal prostate but highly expressed in adenocarcinoma of the prostate and a characteristic sub-cellular distribution among normal, benign hyperplasia, and adenocarcinoma of the prostate.
|
22095517 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Incorporating well-characterized pharmacodynamic markers, such as HEXIM1 and other genes described here, can provide a better understanding of potential efficacy and toxicity associated with inhibiting BET family proteins and informs early clinical decisions on BET inhibitor development programs.Mol Cancer Ther; 16(2); 388-96.©2016 AACR.
|
27903752 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Incorporating well-characterized pharmacodynamic markers, such as HEXIM1 and other genes described here, can provide a better understanding of potential efficacy and toxicity associated with inhibiting BET family proteins and informs early clinical decisions on BET inhibitor development programs.Mol Cancer Ther; 16(2); 388-96.©2016 AACR.
|
27903752 |
2017 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Increased HEXIM1 expression caused differentiation and inhibited proliferation and metastasis of cancer cells.
|
31805991 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Known inhibitors of KDM5B were also able to induce HEXIM1 expression, inhibit cell proliferation, induce differentiation, potentiate sensitivity to cancer chemotherapy, and inhibit breast tumor metastasis.
|
31805991 |
2019 |